Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 8Stomach Neoplasms 6Colonic Neoplasms 6Rectal Neoplasms 4Carcinoma, Hepatocellular 4Breast Neoplasms 2Biliary Tract Neoplasms 2Unspecified Adult Solid Tumor, Protocol Specific 1Pancreatic Neoplasms 1Immunotherapy 1Drug-Related Side Effects and Adverse Reactions 1Carcinoma, Non-Small-Cell Lung 1Advanced Pancreatic Cancer 1Adenocarcinoma 1

Interventions

Amifostine 12Cisplatin 10Radiotherapy 8Etoposide 8Cyclophosphamide 5Paclitaxel 4Filgrastim 4Gemcitabine 3Cytarabine 3Carboplatin 3denileukin diftitox 2apatinib 2Vincristine 2Pyridoxine 2Irinotecan 2Ifosfamide 2Fibroblast Growth Factor 7 2Epoetin Alfa 2Doxorubicin 2Dexamethasone 2Chemotherapy, Adjuvant 2Bleomycin 2uridine triacetate 1sargramostim 1peginterferon alfa-2b 1pegfilgrastim 1pegaspargase 1eribulin 1camrelizumab 1Vitamin E 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Drug-Related Side Effects and Adverse Reactions × Tegafur × Clear all
NCT02447679 2017-02-07

Oral Thalidomide and Tegafur-uracil to Decrease Hepatocellular Carcinoma Recurrence

Chang Gung Memorial Hospital

Phase 2 Completed
40 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡